Video

How do we get the next 10 years right? w/ Joanna Shields, CogX

For the opening keynote of CogX 2020, our CEO Joanna Shields shared inspiration for the next decade, and answered the question “how do we get the next 10 years right”?

We had entered 2020 with such high hopes and dreams for the innovations that awaited us in the coming decade. Yet we were barely out of the gates when our world of infinite possibilities was brought to its knees by a deadly virus. The challenges that followed have been unprecedented in our lifetimes. 

As the disease raged through our communities and lockdowns were enforced, we all watched the daily news recount the number of souls who had lost their lives to COVID-19.  The profound economic shock continues to reverberate, and expose deep inequities in our society and in how we care for our citizens.

Our journey into this strange new normal also made us painfully aware of our own vulnerabilities and the fragility of human life. Above all, we have been reminded that our most valuable currency is not measured in wealth or possessions, but rather through our health.  

So, why can’t we build a world where no disease goes untreated? Why, with all of the advances in technology, are so many people still suffering from disease? The economic and development models urgently need to change. Patients deserve better. We must leverage breakthrough technologies for the benefit of all.

Above all, getting the next 10 years right demands leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all.

Watch the full speech here:


More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020